Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)

• Status: Active, not recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shahid Beheshti University of Medical Sciences
• Collaborator: Behnam Daheshpour Charity Organization, Tehran, Iran
• Treatments: Curcumin

Criteria

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the prostate

• Candidate for External Beam Radiotherapy

• ECOG performance status 0-2

Exclusion Criteria:

• Patients with Metastatic Prostate Cancer

• Patients with Kidney & Liver dysfunction

• Gastrointestinal disorders such as IBD, reflux and peptic ulcers

• Any adverse reaction to curcumin